96
Participants
Start Date
August 31, 2016
Primary Completion Date
May 31, 2018
Study Completion Date
August 31, 2018
SER-262
SER-262 is a rationally designed, multi-strain Ecobiotic® microbiome therapeutic produced synthetically by in vitro fermentation. It is a consortium of anaerobic, commensal bacteria in spore form, encapsulated for oral administration.
Placebo
Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
Montefiore Medical Center, The Bronx
University of Rochester Medical Center, Rochester
Anne Arundel Health System Research Institute, Annapolis
Infectious Disease Associates of Central Virginia, Lynchburg
Clinical Research Atlanta, Stockbridge
Emory University Hospital, Atlanta
Omega Research Consultants, Orlando
San Marcus Research Clinic, Inc., Miami
North Alabama Research Center, LLC, Athens
Remington Davis, Columbus
Regional Infectious Diseases & Infusion Center, Lima
Henry Ford Health System, Detroit
Mayo Clinic, Rochester
Mercury St. Medical Group, Butte
Sundance Clinical Research, LLC, St Louis
Quality Clinical Research, Omaha
Baylor Scott & White Research Institute, Temple
Snake River Research, Idaho Falls
Dr. Hansen Internal Medicine, Bountiful
eStudySite, La Mesa
Lalla-Reddy Medical Corporation, Fountain Valley
Jersey Shore University Medical Center, Neptune City
Collaborators (1)
Pharm-Olam International
INDUSTRY
Seres Therapeutics, Inc.
INDUSTRY